Northwestern Medicine investigators have uncovered new insights into how intercellular "glue" functions to enable ...

You are free to share (copy and redistribute) this article in any medium or format and to adapt (remix, transform, and build upon) the material for any purpose, even commercially within the parameters ...

NEWTON, MA, USA I March 19, 2025 I Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that ...

ABSTRACT: Many infectious diseases are treated with antibiotics and antivirals. But the emergence of antimicrobial-resistant strains and mutant microorganisms has made antimicrobial resistance a major ...

Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of ...

School of Chemistry and Chemical Engineering, University of Jinan, Jinan 250022, P. R. China Zibo City Engineering Research Center for New Pollution Monitoring and Governance, Shandong Vocational ...

"Alzheimer's disease is a brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to ...

PMN310, the Company’s lead product candidate for the treatment of AD, is a differentiated, humanized monoclonal antibody that ...

Today's Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals (NASDAQ: ABOS) CEO Daniel ...

Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for ...

BUT WE KNOW THERE’S THESE TOXIC AGGREGATES. THEY’RE CALLED OLIGOMERS. THEY CAN START TO FORM MORE THAN A DECADE BEFORE SYMPTOMS APPEAR AND BEFORE OTHER KNOWN DISEASE MARKERS FORM. THE ABILITY ...